ClinicalTrials.gg
CompletedNCT04178447Updated Nov 18, 2020

Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function

A Phase 1 interventional study of Glepaglutide in Renal Impairment, sponsored by Zealand Pharma. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-18.

Sponsored by Zealand Pharma · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jul 2020, 6 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Renal Insufficiency with a site in Hungary — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Hungary.

Enrollment
19th of 20
16 · median 42
Started
2019
with 2 others
Phase 1
9 of 23
none open now
Registered
18th of 23
by date

Among the 23 studies in Renal Insufficiency with a site in Hungary, this one is the 19th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2019, is one of 9 in phase 1, and was the 18th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 23 studies in Renal Insufficiency with a site in Hungary are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Hungary have not opened yet or have stopped. Only those recruiting at a site in Hungary →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Renal Insufficiency with a site in Hungary, or all of them as a file.
02

Study summary

This is two stage design, open-label, multi-center, non-randomized trial evaluating the PK of a single, subcutaneous dose of 10 mg glepaglutide in subjects with varying degrees of renal function. The renal function will be calculated by the estimated glomerular filtration rate (eGFR) according to the Modification of Diet in Renal Disease (MDRD) equation.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All subjects

    1. Able to understand and willing to sign the
    2. values as defined in in the arms
    3. Willing and able to comply with the study requirements
    4. Male and female subjects age 18 to 70 years (both inclusive) at the time of informed consent
    5. 20.0 - 30.0 kg/m2 both inclusive
    6. Must be willing to comply with the , sperm-donation requirements, and study restrictions.

      Renally Impaired Subjects (in Addition)

    7. Subject has a stable disease, including disease(s) associated with renal impairment, under medical control (ie, no changes in medication within 30 days prior to study drug administration). Stable renal impairment, defined as no change in disease status within 3 months before screening.

Exclusion criteria

Exclusion Criteria:

All Subjects

  1. Suspicion of , intolerance, or allergy to glepaglutide
  2. History of alcohol or drug abuse
  3. abnormal medical history, abnormal findings on physical examination, vital signs, clinically significant abnormalities on 12-lead , or laboratory tests at Screening that the Investigator judges as likely to interfere with the objectives of the study or the safety of the subject except for conditions associated with renal impairment in subjects with renal impairment
  4. Uncontrolled treated/untreated hypertension (defined as a mean of 3 repeated measurements for systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg); current or documented history of repeated clinically significant hypotension or severe episodes of orthostatic hypotension (systolic blood pressure \< 90 mmHg and/or diastolic blood pressure \< 50 mmHg)
  5. Acute illness within 14 days prior to dosing unless mild in severity and approved by the Investigator and Sponsor's medical representative
  6. Presence of active infection requiring antibiotics. Ingestion of alcohol within 72 hours prior to study drug administration and during PK sampling period including Follow-Up
  7. Participation in another drug study within 30 days prior to study drug administration or exposure to more than three new investigational agents within 12 months prior to study drug administration
  8. Previous exposure to GLP-1, GLP-2, human growth hormone, somatostatin, or analogues thereof within 3 months prior to Screening. Use of dipeptidyl peptidase-4 inhibitors within 3 months prior to Screening
  9. Previous exposure to glepaglutide
  10. Donation or loss of more than 450 mL blood during the 3 months before the start of Screening
  11. Female subjects who are breastfeeding, pregnant, or planning to become pregnant during the study
  12. Positive serology for surface antigen (HBsAg), virus antibody (anti-HCV) or antibodies (anti-HIV)-1/2, unless the absence of an active hepatitis B/C infection is confirmed by a polymerase chain reaction (PCR) test, at Screening
  13. Positive urine screen of drugs of abuse (if not due to concomitant medication) or alcohol breath test at Screening and/or Day -1
  14. Legal incapacity or limited legal capacity

    Renally Impaired Subjects (in Addition)

  15. Acute renal failure (as judged by the Investigator)
  16. Renal impairment requiring dialysis
  17. History of kidney transplant regardless of functionality
  18. Serum albumin concentration \<25 g/L
  19. concentration \<100 g/L
  20. Medications known to affect the elimination of serum creatinine (e.g., trimethoprim or cimetidine) and competitors of renal tubular secretion (e.g., probenecid) within 60 days prior to study drug administration

    Subjects With Normal Renal Function (in Addition)

  21. Significant medical history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator -
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Group 1: ESRD subjects not on dialysis or severe RI

    subjects with eGFR \<15 mL/min/1.73 m2) or (eGFR 15 to \<30 mL/min/1.73 m2)

    Drug: Glepaglutide

  • Experimental
    Group 2: normal renal function

    subjects with eGFR ≥90 mL/min/1.73 m2

    Drug: Glepaglutide

  • Experimental
    Group 3: moderate RI

    subjects with eGFR 30 to \<60 mL/min/1.73 m2

    Drug: Glepaglutide

  • Experimental
    Group 4: mild RI

    subjects with eGFR 60 to \<90 mL/min/1.73 m2

    Drug: Glepaglutide

Interventions

  • Single dose of Glepaglutide 10 mg

    Also known as: ZP1848

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Variables

    AUC0-168 area under the concentration-time curve (AUC) from time 0 to 168 hours Cmax maximum observed plasma concentration

    Time frame: 11 days

Secondary outcomes

  1. Safety Variables

    Number of subject with AE/SAE as a measure of safety and tolerability

    Time frame: 11 days

07

Study locations

3 sites
  • Fázis I-es Klinikai Farmakológiai
    Budapest, 1077, Hungary
  • Szent Imre Egyetemi Oktatókórház
    Budapest, 1115, Hungary
  • Specjalistyczne Centrum Medyczne - Prywatny Szpital
    Kraków, 31-559, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Jul 2020, 7 months.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2019
First posted
Nov 26, 2019
StartActual
Dec 10, 2019
Primary completionActual
Jul 14, 2020
CompletionActual
Jul 14, 2020
Last update
Nov 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04178447
Lead sponsor
Zealand Pharma
Responsible party
Sponsor
First posted
Nov 26, 2019
Start date
Dec 10, 2019
Primary completion
Jul 14, 2020
Completion
Jul 14, 2020
Last update
Nov 18, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glepaglutide

Start the discussion